Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Impedimed Limited ( (AU:IPD) ) is now available.
ImpediMed Limited has announced a change in the interests of its director, Ms. Janelle Delaney, who has acquired an additional 98,347 ordinary shares, bringing her direct holdings to 1,881,481 shares. This acquisition was made through the issuance of shares in lieu of 15% of her director fees for the quarter ended September 30, 2025. The announcement reflects the company’s ongoing practices in managing director compensation and may have implications for shareholder perceptions of director alignment with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices for the measurement of fluid status and body composition. The company’s primary products are designed to assist in the management of conditions such as lymphedema and heart failure, with a market focus on improving patient outcomes through innovative technology.
Average Trading Volume: 1,808,782
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
See more insights into IPD stock on TipRanks’ Stock Analysis page.